Delisting riskPopularity #4,595
MBAI · NASDAQ · Biotechnology

Check-Cap (MBAI)

Maintains legacy C-Scan assets while pursuing a merger with embodied-AI operator MBody.

$6.08
vs last close−0.30 (−4.73%)

13F · 13D/G · Form 4

Insiders767.12%7.69M shares
5 holders · as of Sep 18, 2026
Adds to767.12%

1.00M company shares as of Aug 21, 2026 · holders as of their latest filing

These groups come from separate filings that can overlap, so they add to 767.12%; nothing is left for Other.

13F · 13D/G · Form 4

HolderStakeSharesDate
Regan McMillan McGeeInsiderdirector
684.01%6.86Mfiled Sep 18, 2026
John Alexander FowlerInsiderdirector, officer: Chief Executive Officer
66.81%670,064filed Sep 18, 2026
Timothy John HaydenInsiderofficer: Chief Financial Officer
7.95%79,717filed Sep 18, 2026
Scott Robertson WaltersInsiderdirector
7.95%79,717filed Sep 18, 2026
Kai Michael Toft SorensenInsiderdirector
0.40%4,028filed Sep 18, 2026

13F

No 13F holders on record.

13D/G · 5% or more, as filed

No 13D/G filer at 5% or more on record.

Form 4

Latest trades

No open-market trades in the last 12 months.

House and Senate disclosures

Not reported.